QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires

2026-03-02 02:38:12

Matthew Strobeck, a Board Director at **QuidelOrtho Corp. **(QDEL +0.18%), reported the purchase of 10,000 common shares on Feb. 13, 2026, for a total transaction value of ~$240,000, as disclosed in a SEC Form 4 filing.

Transaction summary

Metric	Value
Shares traded	10,000
Transaction value	$239,586.00
Post-transaction shares (direct)	27,775
Post-transaction value (direct ownership)	$655,000

_Transaction value based on SEC Form 4 reported price ($23.96); post-transaction value based on Feb. 13, 2026 market close ($23.58). _

Key questions

What proportion of Matthew Strobeck’s ownership was affected by this purchase?
This acquisition represented 13.78% of his total reported holdings and 56.26% of his direct stake.
What is the structure of Strobeck’s post-transaction holdings?
After the trade, Strobeck holds 27,775 shares directly and 54,775 shares indirectly through UGMA accounts and Birchview Fund, LLC, with total beneficial ownership of approximately 82,550 shares.

Expand

NASDAQ: QDEL

QuidelOrtho

Today’s Change

(0.18%) $0.04

Current Price

$22.74

Key Data Points

Market Cap

$1.5B

Day’s Range

$21.99 - $22.76

52wk Range

$19.50 - $41.40

Volume

1.1M

Avg Vol

1.1M

Gross Margin

39.85%

Company overview

Metric	Value
Price	$22.74
Revenue (TTM)	$2.73B
Net Loss (TTM)	$1.13B
1-year price change	-44.37%

*Price and 1-year performance calculated using Feb. 28, 2026 as the reference date.

Company snapshot

QuidelOrtho Corporation is a global diagnostics testing solutions company with a broad portfolio spanning laboratory, transfusion medicine, point-of-care, and molecular testing platforms. Its client base includes healthcare providers, laboratories, blood banks, donor centers, and retail channels globally.

What this transaction means for investors

Only two years after QuidelOrtho fired its previous President and CEO and substantial workforce layoffs, the pharmaceutical company is still recovering from its structural changes. Share prices have been down for five consecutive years and have fallen ~23% so far in 2026 (as of Feb. 28). And now, the company has to replace yet another major executive, after current CFO Joseph M. Busky, announced his retirement, and QuidelOrtho has until June to find his replacement, as that’s when the retirement goes into effect.

QuidelOrtho reported its Q4 FY 2025 earnings on Feb. 11, and it closed the fiscal year with a 1.89% year-over-year (YoY) decline in revenue, marking the third straight year of declining annual revenue.

It also marked the third straight year of operating at a net loss and with negative earnings per share (EPS). With years of consistent financial and stock declines, QuidelOrtho is one of the less appealing stocks in the pharmaceutical market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.